FDA approval of semaglutide could help Novo Nordisk access unexploited obesity market

Before the end of the week, the FDA will reveal its verdict on Novo Nordisk's obesity treatment semaglutide. According to Sydbank analyst Søren Løntoft Hansen, this is a crucial approval for the Danish pharmaceutical company.

Photo: Stine Tidsvilde

On Friday at the latest, the US Food and Drug Administration (FDA) will decide whether to approve Novo Nordisk's molecule semaglutide for treating obesity.

According to the Danish bank Sydbank's Chief Equity Analyst Søren Løntoft Hansen, the outcome will be crucial for the Danish pharmaceutical company, which is already on the obesity market with the drug Saxenda.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs